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Graft-versus-host disease (GVHD) is a frequent complication in patients receiving allogeneic 
hematopoietic cell transplantation (HCT). In acute GVHD, the donor immune cells attack and destroy 
the cells of the transplant recipient in various organs, including the gut, skin and liver. Mortality of 
patients with acute GVHD is correlated with the severity and location of gastrointestinal involvement. 
Acute GVHD of the upper gut manifests as anorexia, nausea, vomiting and diarrhea, which can be 
controlled by low doses of steroids, while acute GVHD of the mid-gut leads to more severe 
gastrointestinal problems that require higher doses of steroids, requiring increased 
immunosuppression and leading to non-relapse-related mortality. The ability to identify and treat 
patients with severe GVHD before clinical onset could potentially reduce patient side effects and 
deaths. Several clinical studies have found candidate biomarkers in patient plasma that modulate 
the immune response or indicate tissue damage in acute GVHD. To expand upon these efforts, Drs. 
John Hansen, George McDonald and colleagues in the Clinical Research Division utilized proteomic 
analysis of plasma to identify novel proteins associated with GVHD. 
 The researchers analyzed proteins and protein fragments in patients' serum by mass spectrometry 
in collaboration with the laboratory of Dr. Samir Hanash (Public Health Sciences Division). Several 
proteins were detected at high levels only in patients who later developed severe GVHD compared 
to serum of patients without GVHD. A soluble fragment of the protein T cell Ig and mucin domain 3 
(Tim-3) was one of the proteins identified. Importantly, increased levels of Tim-3 were detected 
before clinical onset of severe mid-gut GVHD compared to upper-gut GVHD. A microbead assay for 
detecting Tim-3 in individual serum samples was developed by the FHCRC Cytokine Laboratory 
Shared Resource, led by Rick Lawler. Using a larger 185-patient cohort, Hansen et al. detected 
significantly higher levels of soluble Tim-3 in the plasma of patients with the more severe mid-gut 
GVHD compared to those with upper-gut GVHD (P=0.005), those without GVHD (P=0.002) and 
normal controls (P<0.0001, see figure).  In a 64-patient cohort with serum samples three weeks after 
tranplant, Tim-3 was the strongest univariate risk factor examined to predict mid-gut GVHD 
development.  The sample size was too small to perform multivariate analysis with other GVHD risk 
factors. 
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The Tim-3 receptor regulates the immune response by suppressing the activation of T lymphocytes. 
Tim-3 is expressed on the cell surface of activated effector T cells and mediates its suppressive 
function by binding the ligand galectin-9. Tim-3 is also expressed on activated B cells, dendritic cells, 
and natural killer (NK) cells. The researchers detected a soluble form of Tim-3 in circulation that 
contained the extracellular domain of the receptor, but lacked the transmembrane and intracellular 
portions of the protein. In addition, cell-surface expression of Tim-3 was significantly increased in 
CD8+ T lymphocytes from patients with more severe GVHD (P=0.01) as determined by flow 
cytometry. 
 While the mechanism for generating soluble Tim-3 is unknown, previous studies have shown that 
defective Tim-3 signaling exacerbates autoimmune reactivity. In a mouse model of GVHD, blocking 
the interaction of Tim-3 with its ligand galectin-9 resulted in a more severe GVHD reaction (Oikawa 
et al., 2006). Results from a different mouse model using soluble a Tim-3 fusion protein further 
suggest that soluble Tim-3 can inhibit the negative regulatory activity of Tim-3 on immune cells and 
inflammation, resulting in more severe GVHD (Veenstra et al., 2012). Conversely, reducing soluble 
Tim-3 levels in plasma could serve as a treatment to reduce severity of GVHD reactions by allowing 
normal function of Tim-3 in regulating the immune response. 
"One key concept here is that measuring Tim-3 before a patient becomes sick with GVHD is a little 
like having a crystal ball -- to predict the future before it happens," according to Dr. McDonald.  The 
goal is to develop a panel of biomarkers to treat patients for GVHD even before the disease 
appears. Current and future studies will examine how well serum levels of Tim-3 perform as a 
predictor of the onset of more severe GVHD, in comparison or in combination with twenty-two other 
putative biomarkers of GVHD previously reported in the literature. Dr. McDonald surmises that 
"because Tim-3 plays a role in immune regulation, the correlation of blood Tim-3 levels with more 
severe GVHD might lead to deeper insight into the cellular mechanisms of GVHD and possibly to 
novel therapies." 
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Image modified from the manuscript 
Levels of Tim-3 are significantly higher in the bloodstream of 
patients about to develop severe GVHD than in transplant 
patients who will never develop GVHD. Box plots represent 
serum levels detected by a Tim-3 microbead assay showing 
25th, 50th, and 75th percentiles; whiskers indicate 5th and 95th 
percentiles. 
 
